{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:32:23Z","timestamp":1793111543863,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharming Healthcare, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03605-4","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:54:53Z","timestamp":1777708493000},"page":"3105-3123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison"],"prefix":"10.1007","volume":"43","author":[{"given":"John","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal","family":"Narsipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Relan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Roskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketsia","family":"Habimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kilvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"1","key":"3605_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132\u201350.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"3605_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaci.2024.12.1079","volume":"155","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Soteres DF, Craig TJ, et al. Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines. J Allergy Clin Immunol. 2025;155(3):726\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3605_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","volume":"112","author":"MA Riedl","year":"2014","unstructured":"Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase\u00a03, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163\u201369.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3605_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","volume":"126","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821\u201327.e14.","journal-title":"J Allergy Clin Immunol"},{"key":"3605_CR5","doi-asserted-by":"crossref","unstructured":"Riedl M, Narsipur N, Jones D, et al. Re-analysis of recombinant C1 inhibitor (rhC1-INH) clinical data with contemporary time-to-event endpoint definitions. Poster presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 6\u201310, 2025; Orlando, Florida.","DOI":"10.1016\/j.anai.2025.08.116"},{"key":"3605_CR6","unstructured":"Ruconest. Prescribing information. Pharming Healthcare Inc; 2020."},{"key":"3605_CR7","unstructured":"Ekterly. Prescribing information. KalVista Pharmaceuticals, Inc; 2025."},{"issue":"1","key":"3605_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2314192","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"3605_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-025-00955-6","volume":"21","author":"HH Li","year":"2025","unstructured":"Li HH, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Magerl M, et al. Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks. Allergy Asthma Clin Immunol. 2025;21(1):1\u201311.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"3605_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1017\/rsm.2025.10","volume":"16","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Liu J, Alemayehu D, et al. A critical assessment of matching-adjusted indirect comparisons in relation to target populations. Res Synth Methods. 2025;16(3):569\u201374.","journal-title":"Res Synth Methods"},{"issue":"2","key":"3605_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jmahp12020006","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, et al. Methods for indirect treatment comparison: results from a systematic literature review. J Mark Access Health Policy. 2024;12(2):58\u201380.","journal-title":"J Mark Access Health Policy"},{"issue":"6","key":"3605_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"6","key":"3605_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"3605_CR14","unstructured":"NICE Decision Support Unit. NICE DSU technical support document 1: introduction to evidence synthesis for decision making. Updated April 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395870\/pdf\/Bookshelf_NBK395870.pdf. Accessed 27 Jan 2026."},{"key":"3605_CR15","unstructured":"Institute for Clinical and Economic Review. Value assessment framework. Updated September 25, 2023. https:\/\/icer.org\/wp-content\/uploads\/2025\/12\/ICER_2023_2026_VAF_For-Publication_112525.pdf. Accessed 27 Jan 2026."},{"key":"3605_CR16","unstructured":"Higgins J, Thomas J, Chandler J, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current. Accessed 27 Jan 2026."},{"key":"3605_CR17","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal and highly specialised technologies evaluation: user guide for company evidence submission template. Updated December 3, 2024. https:\/\/www.nice.org.uk\/process\/pmg24. Accessed 27 Jan 2026."},{"key":"3605_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"3605_CR19","first-page":"1","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:1\u20139.","journal-title":"BMJ"},{"key":"3605_CR20","doi-asserted-by":"crossref","unstructured":"Davis-Lorton M, Tachdjian R, Saharia P, et al. Systematic literature review of recombinant human C1 esterase inhibitor (rhC1-INH) and other products for the on-demand treatment of hereditary angioedema attacks. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research 2025 Annual Meeting; May\u00a013\u201316, 2025; Montreal, QC, Canada.","DOI":"10.1016\/j.jval.2025.04.116"},{"key":"3605_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-12-93","volume":"12","author":"S Cope","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:1\u201317.","journal-title":"BMC Med"},{"key":"3605_CR22","doi-asserted-by":"crossref","unstructured":"Tachdjian R, Narsipur N, Bernstein JA, et al. Clinician perspectives on modifiers of observed treatment effect in on-demand hereditary angioedema (HAE) therapy trials. Poster presented at: American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting; November 6\u201310, 2025; Orlando, FL.","DOI":"10.1016\/j.anai.2025.08.130"},{"key":"3605_CR23","doi-asserted-by":"crossref","unstructured":"Manning ME, Narsipur N, Anderson J, et al. Mapping patient-reported outcome measures across clinical trials in hereditary angioedema (HAE). Poster presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 6\u201310, 2025; Orlando, Florida.","DOI":"10.1016\/j.anai.2025.08.134"},{"key":"3605_CR24","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Integrated Review, NDA 219301, EKTERLY (sebetralstat). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/219301Orig1s000IntegratedR.pdf. Accessed 17 Nov 2025."},{"key":"3605_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.b1147","volume":"338","author":"F Song","year":"2009","unstructured":"Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:1\u20137.","journal-title":"BMJ"},{"issue":"1","key":"3605_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","volume":"10","author":"D Geba","year":"2021","unstructured":"Geba D, Mohd Sani J, Gascon M, et al. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10(1):51\u20136.","journal-title":"J Drug Assess"},{"key":"3605_CR27","doi-asserted-by":"crossref","unstructured":"Radojicic C, Burnette A, van Kooten S, et al. Patient-reported anxiety impacts utilization of injectable on-demand treatment of hereditary angioedema attacks. Poster presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; October 24\u201328, 2024; Boston, MA.","DOI":"10.1016\/j.anai.2024.08.117"},{"issue":"1","key":"3605_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13223-024-00903-w","volume":"20","author":"SD Betschel","year":"2024","unstructured":"Betschel SD, Caballero T, Jones DH, et al. The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. Allergy Asthma Clin Immunol. 2024;20(1):43.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03605-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:33:36Z","timestamp":1793108016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03605-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3605"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03605-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Anderson is a speaker bureau member for CSL Behring, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Takeda, AstraZeneca, and GSK; has received consulting fees from CSL Behring, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Pharvaris, Ionis Pharmaceuticals, Takeda, and Novartis AG; and is a clinical trial investigator for BioCryst Pharmaceuticals, CSL Behring, Pharvaris, KalVista Pharmaceuticals, Astria Therapeutics, Takeda, Novartis AG, and Celldex Therapeutics. Douglas Jones is a consultant for Pharming Healthcare, Inc., KalVista Pharmaceuticals, Takeda, CSL Behring, BioCryst Pharmaceuticals, and Pharvaris. Andrew Smith reports financial relationships with AstraZeneca, BioCryst Pharmaceuticals, OptiNose, US, Inc, Pharming Group, N.V., and Takeda. H. Henry Li has received research or consulting support from or provided speaker presentations for CSL Behring, BioCryst Pharmaceuticals, Pharvaris, Argo Biopharma, KalVista Pharmaceuticals, Takeda, Intellia Therapeutics, Pharming Healthcare, Inc., and Ionis Pharmaceuticals. Emily Aiello, Neil Roskell, Adam Gough, Sakshi Jindal, Ketsia Habimana, and Hannah Kilvert are employed by Lumanity, which received consulting fees from Pharming Healthcare, Inc. Nihal Narsipur, Anurag Relan, and Amanda Harrington are employees of Pharming Healthcare, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on previously published clinical trials and did not involve any new studies with human participants or animals performed by any of the authors. For the trials included in this analysis, the original trial protocols were approved by an institutional review board or ethics committee, and the trials were each conducted in accordance with the principles of the Declaration of Helsinki. All trial participants provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}